• 1
    Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72: 247259.
  • 2
    Connolly JO, Woolfson RG. A critique of clinical guidelines for detection of individuals with chronic kidney disease. Nephron Clin Pract. 2009; 111: 6973.
  • 3
    Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep. 2010; 10: 3742.
  • 4
    Giannelli SV, Patel KV, Windham BG, Pizzarelli F, Ferrucci L, Guralnik JM. Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc. 2007; 55: 816823.
  • 5
    Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008; 17: 127132.
  • 6
    K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1S246.
  • 7
    Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006; 114: 10831087.
  • 8
    Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol. 2008; 21: 927.
  • 9
    Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia. 2009; 11: 269276.
  • 10
    Maher AD, Crockford D, Toft H, Malmodin D, Faber JH, McCarthy MI, Barrett A, Allen M, Walker M, Holmes E, Lindon JC, Nicholson JK. Optimization of human plasma 1H NMR spectroscopic data processing for high-throughput metabolic phenotyping studies and detection of insulin resistance related to type 2 diabetes. Anal Chem. 2008; 80: 73547362.
  • 11
    Sinclair AJ, Viant MR, Ball AK, Burdon MA, Walker EA, Stewart PM, Rauz S, Young SP. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases–a diagnostic tool? NMR Biomed. 2010; 23: 123132.
  • 12
    Zira AN, Theocharis SE, Mitropoulos D, Migdalis V, Mikros E. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J Proteome Res. 2010; 9: 40384044.
  • 13
    Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta. 2008; 624: 269277.
  • 14
    Wang JN, Zhou Y, Zhu TY, Wang X, Guo YL. Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res. 2008; 7: 35973601.
  • 15
    Kim CD, Kim EY, Yoo H, Lee JW, Ryu do H, Noh DW, Park SH, Kim YL, Hwang GS, Kwon TH. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A-or tacrolimus-based immunosuppression. Transplantation. 2010; 90: 748756.
  • 16
    Psihogios NG, Kalaitzidis RG, Dimou S, Seferiadis KI, Siamopoulos KC, Bairaktari ET. Evaluation of tubulointerstitial lesions’ severity in patients with glomerulonephritides: an NMR-based metabonomic study. J Proteome Res. 2007; 6: 37603770.
  • 17
    Tzovaras VT, Psychogios NG, Kostara CE, Bairaktari ET, Elisaf MS. Evaluation of the proximal tubular function in individuals with primary renal hypouricemia: an NMR-based metabonomic study. NMR Biomed. 2009; 22: 10721083.
  • 18
    Kidney Disease Outcome Quality Initiative, Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1S246.
  • 19
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461470.
  • 20
    World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med. 2002; 48: 206208.
  • 21
    Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995; 67: 793811.
  • 22
    De Meyer T, Sinnaeve D, Van Gasse B, Rietzschel ER, De Buyzere ML, Langlois MR, Bekaert S, Martins JC, Van Criekinge W. Evaluation of standard and advanced preprocessing methods for the univariate analysis of blood serum 1H-NMR spectra. Anal Bioanal Chem. 2010; 398: 17811790.
  • 23
    Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007; 6: 469479.
  • 24
    Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, van Ommen B, Smilde AK. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem. 2006; 78: 567574.
  • 25
    Foxall PJ, Mellotte GJ, Bending MR, Lindon JC, Nicholson JK. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int. 1993; 43: 234245.
  • 26
    Le Moyec L, Pruna A, Eugène M, Bedrossian J, Idatte JM, Huneau JF, Tomé D. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 1993; 65: 433439.
  • 27
    Chesney RW, Han X, Patters AB. Taurine and the renal system. J Biomed Sci. 2010; 17: S1S4.
  • 28
    Bergstrom J, Alvestrand A, Furst P, Lindholm B. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion. J Intern Med. 1989; 226: 189194.
  • 29
    Qureshi GA, Baig SM. Application of high performance liquid chromatography in study of sulphur amino acid metabolism in uremic patients. Biochem Mol Biol Int. 1993; 29: 359368.
  • 30
    Blanchet MR, Langlois A, Israel-Assayag E, Beaulieu MJ, Ferland C, Laviolette M, Cormier Y. Modulation of eosinophil activation in vitro by a nicotinic receptor agonist. J Leukoc Biol. 2007; 81: 12451251.
  • 31
    Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther. 2008; 117: 5276.
  • 32
    McGregor DO, Dellow WJ, Robson RA, Lever M, George PM, Chambers ST. Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney Int. 2002; 61: 10401046.
  • 33
    Sizeland PCB, Chambers ST, Lever M, Bason LM, Robson RA. Organic osmolytes in human and other mammalian kidneys. Kidney Int. 1993; 43: 448453.
  • 34
    Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kültz D, Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006; 5: 6470.
  • 35
    Lin L, Huang Z, Gao Y, Yan X, Xing J, Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J Proteome Res. 2011; 10: 13961405.